Glutarimide, also known as piperidine-2,6-dione, is an organic compound with the chemical formula C<sub>5</sub>H<sub>7</sub>NO<sub>2</sub>. It is a white crystalline powder formed by the dehydration of the amide of glutaric acid. Glutarimide serves as a core structural component in several pharmacologically active compounds, including thalidomide, lenalidomide, cycloheximide, and glutethimide, which exhibit immunomodulatory, anticancer, or antibiotic properties. As a standalone compound, glutarimide is used in chemical synthesis and research, with no direct therapeutic applications.
Glutarimide is a heterocyclic compound with a six-membered piperidine ring containing two ketone groups at positions 2 and 6, forming a dicarboximide structure. Its molecular formula, C<sub>5</sub>H<sub>7</sub>NO<sub>2</sub>, corresponds to a molecular weight of 113.114 g/mol, with a melting point of 152âÂÂ154 ðC and solubility in water, ethanol, and acetone. It is synthesized by heating glutaric acid with ammonia, followed by dehydration to close the imide ring. N-Acyl-glutarimides are key intermediates in NâÂÂC(O) cross-coupling reactions due to their destabilized amide bond, enabling applications in organic synthesis.
Glutarimide itself lacks direct pharmacological activity but is a critical scaffold in several drugs. Derivatives like thalidomide and lenalidomide bind to cereblon (CRBN), an E3 ubiquitin ligase adaptor, promoting protein degradation and exerting immunomodulatory and anti-angiogenic effects. Cycloheximide inhibits protein synthesis by blocking translation elongation in eukaryotic cells, making it a valuable research tool. Glutarimide antibiotics, such as 9-methylstreptimidone, exhibit antiviral, antitumor, and antifungal activities through protein biosynthesis inhibition. The glutarimide moietyâÂÂs interaction with biological targets underpins its pharmacological versatility.
Glutarimide was first synthesized in the early 20th century from glutaric acid, initially valued for its synthetic utility. Its pharmacological relevance emerged with thalidomide in the 1950s, marketed as a sedative but withdrawn in 1961 after causing thousands of birth defects. ThalidomideâÂÂs reapproval in 1998 for ENL and later for multiple myeloma led to the development of safer IMiDs like lenalidomide. Glutarimide remains a key scaffold in modern drug design, particularly for CRBN-targeted therapies.